CN104774243B - A kind of Eucheuma polypeptide extract and its preparation method and application - Google Patents
A kind of Eucheuma polypeptide extract and its preparation method and application Download PDFInfo
- Publication number
- CN104774243B CN104774243B CN201510163788.2A CN201510163788A CN104774243B CN 104774243 B CN104774243 B CN 104774243B CN 201510163788 A CN201510163788 A CN 201510163788A CN 104774243 B CN104774243 B CN 104774243B
- Authority
- CN
- China
- Prior art keywords
- eucheuma
- polypeptide extract
- preparation
- polypeptide
- supernatant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention discloses a kind of Eucheuma polypeptide extract and its preparation method and application, a kind of polypeptide extract is made in the present invention from Eucheuma raw material, being experimentally confirmed the extract has good platelet aggregation-against, extend bleeding time and clotting time, the new capability of inhibition thrombosis, the extract can be applied to medicine, drug component, prodrug or the health products for preparing platelet aggregation-against or antithrombotic.
Description
Technical field
The invention belongs to biological technical field, and in particular to a kind of Eucheuma polypeptide extract and preparation method thereof and should
With.
Background technology
Eucheuma（Eucheuma）, be also acanthopeltis japonica Okamura, chicken glue dish, belong to the frond plumpness fleshiness of algae, it is cylindric, it is flat pressure or
Flat, radiation or two lateral branchings, the category there are about 20 kinds, and China there are about 5 kinds, be tropical marine alga, have very high medicinal valency
Value.Eucheuma polypeptide component derives from Eucheuma.
Thrombotic diseases are a kind of diseases for having a strong impact on health, often show as myocardial infarction, Ischemic Cerebral Infarction, vein
Thromboembolism.The medicine of clinical treatment thrombotic diseases is broadly divided into anti-platelet drug, anticoagulation medicine and molten at present
Thrombus medicine.Anti-platelet drug, which has, suppresses hematoblastic adhesion, aggregation and release function, so as to prevent thrombosis.
Antiplatelet drug can effectively prevent the generation of angiocardiopathy, and can extend the life cycle of patient, antiplatelet drug
It is increasingly extensive in clinical practice.It is the new platelet aggregation-against of screening that new antiplatelet drug is found from natural active matter
One Critical policies of medicine or prodrug.
And at present there is no the function of document report Eucheuma polypeptide component antithrombotic, do not find at home and abroad to use Eucheuma
Polypeptide component makees the report that antithrombotic reagent or health products use.
The content of the invention
It is an object of the invention to overcome above-mentioned the deficiencies in the prior art, there is provided a kind of Eucheuma polypeptide extract and its system
Preparation Method.
Another object of the present invention is to disclose a kind of new application of Eucheuma polypeptide extract, changes the extraction of Eucheuma polypeptide
Thing can significantly suppress platelet aggregation, prevent thrombosis.
The above-mentioned purpose of the present invention is achieved by following technical solution：
A kind of preparation method of Eucheuma polypeptide extract, is comprised the following steps that：
S1. take fresh Eucheuma to crush, add the HCl solution homogenate that concentration is 15 ~ 25 mmol/L and rough liquid is made,
The addition of the HCl solution adds 8 ~ 12 L by every kilogram of Eucheuma；
S2. appropriate saturated potassium chloride solution is added in rough liquid（Under the conditions of 20 DEG C, the quality of saturated potassium chloride solution is dense
Degree about 25%）, the concentration to potassium chloride is 1.3 ~ 1.8%, and the viscosity of rough liquid is moderately reduced, is easy to subsequent treatment；
S3. step S2 rough liquid is centrifuged, takes supernatant, using gel filtration chromatography point after supernatant coarse filtration
From the HCl solution that concentration is 15 ~ 25 mmol/L elutes, and eluting peak has two groups；
S4. second group of eluted product is collected, after adjusting solution acid alkalinity to pH value 6.0 ~ 7.0, is centrifuged, supernatant
Required extract is made in freeze-drying.
Preferably, the gel column that the gel filtration chromatography uses is glucan G-50 gel column（Sephadex G-50）.
It is highly preferred that the pillar height of the glucan G-50 gel columns is 28 ~ 32 cm, internal diameter width is 1.8 ~ 2.2cm.
Preferably, during the gel filtration chromatography separation, the loading of rough liquid is highly the 5 ~ 10% of gel column pillar height.
Preferably, during the gel filtration chromatography separation, the flow control of eluent is 0.8 ~ 1.2 mL/min.
The supernatant coarse filtration is specially to use 2 ~ 4 layers of filtered through gauze, and the gauze is the conventional yarn of this area filtering
Cloth.
Described in step S1 or S3 centrifuge for low-speed centrifugal separate, the rotating speed specifically centrifuged be 8000 ~ 12000 turns/
Min, centrifugation time are 13 ~ 18 min.
One kind passes through Eucheuma polypeptide extract made from preparation method of the present invention.The present invention by simple experiment,
Such as sodium dodecyl sulfate-polyacrylamide gel electrophoresis（SDS-PAGE）Confirm extract be single electrophoretic band, mainly into
It is divided into the polypeptide component that molecular weight is less than 10 KDa.
Application of the Eucheuma polypeptide extract in platelet aggregation-against or antithrombotic reagent is prepared.
Application of the Eucheuma polypeptide extract in platelet aggregation-against or antithrombotic health products is prepared.
The present invention has found that Eucheuma polypeptide extract has and suppresses platelet aggregation, when extending bleeding by experiment test
Between and clotting time, the new capability of inhibition thrombosis, can apply to prepare antithrombotic reagent or health products, for anti-hemostasis
Myocardial infarction, Ischemic Cerebral Infarction, VTE etc. caused by bolt.
The specifically used form of Eucheuma polypeptide extract of the present invention includes following several：1st, pulvis is can be made into, is used
Physiological saline solution is oral；2nd, injection is can be made into, is used by injection requirement；3rd, can addition sugar beverage processed, mouth is made
Take liquid product.
The present invention without particular/special requirement, can use the use condition of the Eucheuma polypeptide extract at ambient temperature,
Dosage is about：10 ~ 400 μ g/kg/ are daily, make by the condition of polypeptide component based food or medicine, referring concurrently to current city
The antithrombotic reagent in face and the scope of application of health products.
Compared with prior art, the present invention has the advantages that：
Polypeptide extract is made in present invention success from Eucheuma raw material, and being experimentally confirmed the extract has well
Platelet aggregation-against, extend bleeding time and clotting time, the new capability of inhibition thrombosis, the extract can be applied to
Prepare medicine, drug component, prodrug or the health products of platelet aggregation-against or antithrombotic.
Embodiment
The present invention is further explained with reference to specific embodiment, but specific embodiment is not to the present invention
It is limited in any way.Unless stated otherwise, reagent involved in embodiment, method are reagent commonly used in the art and method.
The preparation of the Eucheuma polypeptide extract of embodiment 1
（1）20g Eucheuma mechanical crushings are weighed, is homogenized with the mmol/L of 160 mL 25 HCl solution and rough liquid is made.
（2）Rough liquid is more sticky, adds appropriate saturated potassium chloride solution（Under the conditions of 20 DEG C, saturated potassium chloride solution
Mass concentration is about 25%）Into rough liquid so that the concentration of potassium chloride is 1.3%.
（3）By step（2）Rough liquid centrifuge（8000 turns/min, centrifuge 18 min）, supernatant is collected, with three layers
After filtered through gauze supernatant, separated using glucan G-50 gel filtration chromatographies, the pillar height of gel column is 28 cm, and internal diameter width is
1.8 cm, loading are highly the 5% of gel column pillar height.After ready to balance, the HCl solution that concentration is 25 mmol/L elutes, and washes
The flow control of de- liquid is 0.8 mL/min, obtains two groups of eluting peaks.
（4）Second group of eluted product is collected, after adjusting solution acid alkalinity to pH value 6.0 ~ 7.0, is centrifuged（8000 turns/
Min, centrifuge 18 min）, take supernatant to be freeze-dried, Eucheuma polypeptide extract be made.
Using sodium dodecyl sulfate-polyacrylamide gel electrophoresis（SDS-PAGE）Confirm kylin made from the present embodiment
Dish polypeptide extract is single electrophoretic band, and main component is the polypeptide component that molecular weight is less than 10 KDa.
The preparation of the Eucheuma polypeptide extract of embodiment 2
（1）200g Eucheuma mechanical crushings are weighed, is homogenized with the mmol/L of 2200 mL 15 HCl solution and is made rough
Liquid.
（2）Rough liquid is more sticky, adds appropriate saturated potassium chloride solution into rough liquid so that the concentration of potassium chloride is
1.8%。
（3）By step（2）Rough liquid centrifuge（12000 turns/min, centrifuge 13 min）, supernatant is collected, with three
After layer filtered through gauze supernatant, separated using glucan G-50 gel filtration chromatographies, the pillar height of gel column is 32 cm, internal diameter width
For 2.2 cm, loading is highly the 7% of gel column pillar height.After ready to balance, the HCl solution that concentration is 15 mmol/L elutes,
The flow control of eluent is 1.2 mL/min, obtains two groups of eluting peaks.
（4）Second group of eluted product is collected, after adjusting solution acid alkalinity to pH value 6.0 ~ 7.0, is centrifuged（12000 turns/
Min, centrifuge 13 min）, take supernatant to be freeze-dried, Eucheuma polypeptide extract be made.
Using sodium dodecyl sulfate-polyacrylamide gel electrophoresis（SDS-PAGE）Confirm kylin made from the present embodiment
Dish polypeptide extract is single electrophoretic band, and main component is the polypeptide component that molecular weight is less than 10 KDa.
The preparation of the Eucheuma polypeptide extract of embodiment 3
（1）1000g Eucheuma mechanical crushings are weighed, is homogenized with the mmol/L of 10 L 20 HCl solution and rough liquid is made.
（2）Rough liquid is more sticky, adds appropriate saturated potassium chloride solution into rough liquid so that the concentration of potassium chloride is
1.5%。
（3）By step（2）Rough liquid centrifuge（10000 turns/min, centrifuge 15 min）, supernatant is collected, with three
After layer filtered through gauze supernatant, separated using glucan G-50 gel filtration chromatographies, the pillar height of gel column is 30 cm, internal diameter width
For 2.0 cm, loading is highly the 10% of gel column pillar height.After ready to balance, the HCl solution that concentration is 20 mmol/L elutes,
The flow control of eluent is 1.0 mL/min, obtains two groups of eluting peaks.
（4）Second group of eluted product is collected, after adjusting solution acid alkalinity to pH value 6.0 ~ 7.0, is centrifuged（10000 turns/
Min, centrifuge 15 min）, take supernatant to be freeze-dried, Eucheuma polypeptide extract be made.
Using sodium dodecyl sulfate-polyacrylamide gel electrophoresis（SDS-PAGE）Confirm kylin made from the present embodiment
Dish polypeptide extract is single electrophoretic band, and main component is the polypeptide component that molecular weight is less than 10 KDa.
Influence experiment of the Eucheuma polypeptide extract of embodiment 4 to whole-blood platelet aggregation
Rabbit whole blood blood platelet is obtained using prior art, is specially：Rabbit blood is collected with plastic tube and adds rabbit blood volume 15%
ACD（86mmol/L sodium citrates, 111mmol/L glucose, 53mmol/L citric acids）Anti-freezing.Take whole blood 0.5ml and medicine
Thing（Eucheuma polypeptide extract made from embodiment 1）5min is incubated, then with fibrin ferment (500 U/L) or 20 μm of ol/L glands
Glycosides diphosphonic acid（ADP）Processing, with whole blood aggregometer record aggregate situation, record data, experimental data carries out t inspections.
Shown in specific drug dose and the following Tables 1 and 2 of test result.
Influence (n=4) of the Eucheuma polypeptide extract of table 1 to the rabbit whole blood platelet aggregation of thrombin induction
| Eucheuma polypeptide extract（μg/ml） | Maximum platelet aggregation rate（Ω） | Inhibiting rate（%） | |
| 1 | 0 | 18.75±1.88 | -- |
| 2 | 1.25 | 9.37±1.28 | 50** |
| 3 | 2.5 | 8.25±2.36 | 56** |
| 4 | 5 | 5.62±3.23 | 70** |
*P<0.05, **P<0.01。
The influence (n=4) for the rabbit whole blood platelet aggregation that the Eucheuma polypeptide extract of table 2 is induced ADP
| Eucheuma polypeptide extract（μg/ml） | Maximum platelet aggregation rate（Ω） | Inhibiting rate（%） | |
| 1 | 0 | 11.25±2.65 | -- |
| 2 | 1.25 | 6.00±3.20 | 53.3** |
| 3 | 2.5 | 3.86±1.46 | 65.7** |
| 4 | 5 | 3.13±1.07 | 72.2** |
*P<0.05, **P<0.01。
Can be seen that Eucheuma polypeptide extract from the experimental result of table 1 and table 2 can effectively suppress platelet aggregation.
The Eucheuma polypeptide extract of embodiment 5 is thrombotic on rat carotid artery to influence experiment
It is injected intraperitoneally with 10% chloraldurate 4.5ml/kg by rat anesthesia, a bilateral common carotid artery and vein is separated, through vein
Inject medicine（Eucheuma polypeptide extract made from embodiment 2, use medicine of the Normal Saline configuration concentration for 2 μ g/ μ l
Thing mother liquor）Afterwards, arteria carotis (electric current 1mA, stimulation time are 5 minutes), observation are stimulated with YLS-14B instrument for generating thrombus in small animal
Carotid thrombosis congestion situations, SPSS10.0 statistical analysis softwares are used to experimental data, using q methods of inspection, P ＜ 0.01 think
It is statistically significant.Specific drug dose and test result are as shown in table 3 below.
The influence (n=6) that the Eucheuma polypeptide extract of table 3 is formed to rat suppository
| Group | Dosage | 5 minutes average plugging rates（%） |
| Control group | -- | 79±8 |
| Eucheuma polypeptide extract group | 12.5 μg/kg | 30±26* |
| Eucheuma polypeptide extract group | 25 μg/kg | 11±13* |
| Eucheuma polypeptide extract group | 50 μg/kg | 3±6* |
| Thrombus leads to group | 30 mg/kg | 8±9* |
| Heparin group | 1600 U/kg | 16±20* |
Compared with control group：*P<0.01。
Can be seen that Eucheuma polypeptide extract from the experimental result of table 3 can effectively suppress the shape of rat carotid artery thrombus
Into.
Influence experiment of the Eucheuma polypeptide extract of embodiment 6 to mouse bleeding time and clotting time
（1）The measure in bleeding time（Cut tail method）
50 Kun Ming mices, 18~22g of body weight, male and female half and half, are randomly divided into 5 groups, give high dose respectively（50μ
g/kg）, middle dosage (25 μ g/kg), the medicine of low dosage (12.5 μ g/kg)（Eucheuma polypeptide extract made from embodiment 3,
Use mother liquid medicine of the Normal Saline configuration concentration for 2 μ g/ μ l）, thrombus leads to（30mg/kg）And physiological saline.Small white mouse
30 min after intraperitoneal injection, cut off with scissors at Mouse Tail-tip 0.5cm, from start bleeding when manual time-keeping, every
30s is gently pasted with filter paper at tail point broken ends of fractured bone bleeding, untill when loseing red bloodstain completely on filter paper, is designated as the mouse bleeding
Time, bleeding time most long observation 60min, calculated more than 60min still bleedings by 60min.The time is recorded, each group is shown
Sex differernce is write to compare.
（2）The measure in clotting time（Slide method）
With reference to above-mentioned steps（1）1 h after being administered to mice by intraperitoneal injection, plucks eyeball blood sampling, and blood coagulation is determined with slide method
Time：After mouse takes eye, 2 drop diameter about 5mm drop of blood is respectively dripped at slide both ends, uses manual time-keeping immediately.Every 30s major parts
Pin gently provokes drop of blood ecto-entad once, until observing that two bleed untill liquid all chooses the trace of blood.To choosing since blood sampling
Play the trace of blood to stop, as the clotting time, clotting time most long observation 30min, calculated more than 30min not blood coagulations by 30min.Note
The time is recorded, each group carries out significant difference comparison.
The measurement result in bleeding time and the measurement result in clotting time are as shown in table 4, from table 3 it can be seen that Eucheuma
Polypeptide extract can effectively extend mouse bleeding time and clotting time, and then can effectively suppress the formation of thrombus.
Influence (n=10) of the Eucheuma polypeptide extract of table 4 to mouse bleeding time (BT) and clotting time (CT)
| Group | Dosage | BT（min） | CT（min） |
| Control group | -- | 11.2±4.4 | 1.3±0.4 |
| Eucheuma polypeptide extract group | 12.5 μg/kg | 21.3±8** | 3.3±2.1** |
| Eucheuma polypeptide extract group | 25 μg/kg | 18.7±3.7* | 3.2±1.1** |
| Eucheuma polypeptide extract group | 50 μg/kg | 20.4±6.3** | 3.4±1.5** |
| Thrombus leads to group | 30 mg/kg | 19.2±4.7* | 3.0±1.3* |
Compared with control group：*P<0.05, **P<0.01。
Claims (8)
1. a kind of preparation method of Eucheuma polypeptide extract, it is characterised in that comprise the following steps that：
S1. take fresh Eucheuma to crush, add the HCl solution homogenate that concentration is 15~25mmol/L and rough liquid, the HCl is made
The addition of solution adds 8~12L by every kilogram of Eucheuma；
S2. it is 1.3~1.8% that appropriate saturated potassium chloride solution to the concentration of potassium chloride is added in rough liquid；
S3. step S2 rough liquid is centrifuged, takes supernatant, separated, made using gel filtration chromatography after supernatant coarse filtration
Eluted with the HCl solution that concentration is 15~25mmol/L, eluting peak there are two groups；
S4. second group of eluted product is collected, after adjusting solution acid alkalinity to pH value 6.0~7.0, is centrifuged, supernatant freezing
Dry extract needed for being made；The gel column that the gel filtration chromatography uses is glucan G-50 gel column.
2. the preparation method of Eucheuma polypeptide extract according to claim 1, it is characterised in that the glucan G-50 coagulates
The pillar height of glue post is 28~32cm, and internal diameter width is 1.8~2.2cm.
3. the preparation method of Eucheuma polypeptide extract according to claim 1, it is characterised in that the gel filtration chromatography point
From when, the loading of rough liquid is highly the 5~10% of gel column pillar height.
4. the preparation method of Eucheuma polypeptide extract according to claim 1, it is characterised in that the gel filtration chromatography point
From when, the flow control of eluent is 0.8~1.2mL/min.
5. the preparation method of Eucheuma polypeptide extract according to claim 1, it is characterised in that the supernatant coarse filtration
Specially use 2~4 layers of filtered through gauze.
6. the preparation method of Eucheuma polypeptide extract according to claim 1, it is characterised in that centrifugation point described in step S3
From rotating speed be 8000~12000 turns/min, centrifugation time is 13~18min.
A kind of 7. Eucheuma polypeptide extract according to made from any one of claim 1 to 6 preparation method.
8. application of the Eucheuma polypeptide extract in platelet aggregation-against or antithrombotic reagent is prepared described in claim 7.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510163788.2A CN104774243B (en) | 2015-04-09 | 2015-04-09 | A kind of Eucheuma polypeptide extract and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510163788.2A CN104774243B (en) | 2015-04-09 | 2015-04-09 | A kind of Eucheuma polypeptide extract and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104774243A CN104774243A (en) | 2015-07-15 |
| CN104774243B true CN104774243B (en) | 2018-01-09 |
Family
ID=53616039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510163788.2A Active CN104774243B (en) | 2015-04-09 | 2015-04-09 | A kind of Eucheuma polypeptide extract and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104774243B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105012932A (en) * | 2015-07-29 | 2015-11-04 | 高秀婷 | Spleen tonifying oral liquid and preparation method thereof |
| CN106913858B (en) * | 2017-05-02 | 2020-10-27 | 广东医科大学 | Application of eucheuma polypeptide in preventing and treating pulmonary fibrosis |
| CN109400677B (en) * | 2018-11-22 | 2020-12-15 | 浙江海洋大学 | Eucheuma blood fat reducing tetrapeptide and application thereof |
| CN109369781B (en) * | 2018-11-22 | 2020-12-15 | 浙江海洋大学 | Eucheuma anti-oxidation tetrapeptide and application thereof |
| CN110464742B (en) * | 2019-09-08 | 2021-11-09 | 南方海洋科学与工程广东省实验室(湛江) | Eucheuma extract and application thereof in preparation of medicine for treating organ fibrosis |
| CN114989258B (en) * | 2022-04-29 | 2023-03-24 | 清枫链食苏打饮品(吉林)有限公司 | Application of plant extract composition in preparing product for treating constipation and reducing weight |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101560250A (en) * | 2009-05-22 | 2009-10-21 | 青岛大学 | Extracting method of natural pigment glycosidoprotein in eucheuma |
| CN103951737A (en) * | 2014-04-22 | 2014-07-30 | 钦州市山海生物科技有限公司 | Method for extracting glycotropic protein from seaweed |
-
2015
- 2015-04-09 CN CN201510163788.2A patent/CN104774243B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101560250A (en) * | 2009-05-22 | 2009-10-21 | 青岛大学 | Extracting method of natural pigment glycosidoprotein in eucheuma |
| CN103951737A (en) * | 2014-04-22 | 2014-07-30 | 钦州市山海生物科技有限公司 | Method for extracting glycotropic protein from seaweed |
Non-Patent Citations (4)
| Title |
|---|
| Anticoagulants from marine algae;D.S.McLellan等;《Blood Coagulation and Fibrinolysis》;19920229;第3卷(第1期);第69-77页 * |
| k-卡拉胶热可逆凝胶化行为研究;罗亮 等;《高分子学报》;20031231(第6期);第862-865页 * |
| Platelet aggregation is inhibited by phycolectins;Matsubara等;《Cellular and Molecular Life Science》;19960630;第52卷(第6期);摘要 * |
| 琼枝麒麟菜硫酸化酶的提取纯化及卡拉胶的改性研究;王爱梅;《中国优秀硕士学位论文全文数据库（电子期刊）工程科技I辑》;20150215;第17页"3.1.4 KCl浓度的选择" * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104774243A (en) | 2015-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104774243B (en) | A kind of Eucheuma polypeptide extract and its preparation method and application | |
| EP1927363B1 (en) | An extract for preventing or treating thrombotic diseases | |
| CN109966319B (en) | Raw material of novel rehabilitation liquid and preparation method and application thereof | |
| US20120321704A1 (en) | Compound sea Cucumber Product, Preparation Method, and Dosage Forms Thereof | |
| EP3175861A1 (en) | Pharmaceutical composition for treating cardiovascular or cerebrovascular diseases and preparation method therefor | |
| CN109331038A (en) | A kind of production technology of deer haemin and its preparation method of health care product | |
| KR20140017741A (en) | Pharmaceutical composition comprising the extract of angelica gigas nakai as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| CN102920736B (en) | Preparation method of traditional Chinese medicine leech extract | |
| JP2013503821A (en) | Pharmaceutical composition for the treatment of thrombosis, and its preparation method and use | |
| CN107951964B (en) | Peanut skin extract and grape seed extract compound capsule and production method thereof | |
| CN104721246B (en) | A kind of natural plant extracts preparation for being used to prevent transient cerebral ischemia | |
| WO2009076869A1 (en) | Salvianolic acid of high purity, preparation method and use thereof | |
| CN115429752A (en) | Salvia miltiorrhiza injection and preparation method and application thereof | |
| KR101671847B1 (en) | Compositions for prevention or treatment of thrombosis comprising an extract of Opalopanax elatus | |
| KR20200069962A (en) | Pharmaceutical composition comprising the extract of darae pollen as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR102117896B1 (en) | Composition comprising Extract of Crataegus pinnatifida Bunge for Antithrombosis | |
| CN101380100B (en) | Preparation method of velvet deerhorn liquor | |
| KR20070070292A (en) | Animal and plant herbal composition effective for circulation of blood | |
| CN104523758B (en) | A kind of dried wood-louse extract and its application | |
| CN108969580B (en) | Preparation method and application of blue cloth total tannin | |
| CN113197272A (en) | Small peptide and angelica keiskei freeze-dried powder beverage capable of activating blood vessels and resisting aging and preparation method thereof | |
| CN111529711A (en) | Aloe extract for resisting platelet aggregation and application thereof in PRP preparation | |
| KR20180053254A (en) | Composition containing extract of Paeonia lactiflora or Salvia miltiorrhiza for improving blood circulation | |
| CN104403016A (en) | Folium mori polysaccharide as well as separation and purification preparation method and application thereof | |
| KR20190066491A (en) | Pharmaceutical composition comprising the extracts from the flesh and seed of passion fruit as an effective component for prevention or treatment of thrombosis and health functional food comprising the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200730 Address after: 570100 73-02 Sanshui LANWAN, Xinbu Island, Meilan District, Haikou City, Hainan Province Patentee after: Hainan hetide Marine Resources Development Co.,Ltd. Address before: 524023 No. 2 civilized East Road, Xiashan District, Guangdong, Zhanjiang Patentee before: Zhang Haitao |
|
| TR01 | Transfer of patent right | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20230530 Granted publication date: 20180109 |
|
| PP01 | Preservation of patent right |